Physician profile
Paul Patton
NPI 1437401502
$2,253.53
in general payments reported to CMS, 2019-2025
19 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $173 · 2023: $506 · 2024: $1,448 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070 · Travel and Lodging: $911 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.83 |
| Travel and Lodging | $910.76 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,235.46 | 2024 | Urolift |
| Astellas Pharma US INC | $274.52 | 2022-2024 | Myrbetriq, Veozah |
| Abbvie INC. | $194.26 | 2022-2024 | |
| Endo USA, INC. | $76.56 | 2024-2025 | Xiaflex, Aveed |
| Accord Healthcare, INC. | $61.88 | 2025 | |
| 180 Medical, INC. | $57.46 | 2022-2024 | Gentlecath |
| Astrazeneca Pharmaceuticals LP | $49.28 | 2023 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $47.23 | 2022-2023 | |
| Novo Nordisk INC | $41.14 | 2023 | Wegovy |
| Antares Pharma, INC. | $40.31 | 2024-2025 | Xyosted |
| Olympus America INC. | $32.09 | 2024 | Itind System |
| Ambu INC. | $23.63 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.82 | 2025 | |
| Urogen Pharma, INC. | $18.95 | 2023 | Jelmyto |
| Endo Pharmaceuticals INC. | $18.61 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $16.03 | 2023 | Accrufer |
| Alnylam Pharmaceuticals INC. | $15.27 | 2022 | |
| Halozyme INC | $15.20 | 2023 | |
| Lilly USA, LLC | $13.83 | 2024 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.